Ecotropic virus integration site-1 (EVI1) is frequently expressed in patients with acute myeloid leukemia (AML). Many studies have reported the potential poor prognostic impact of EVI1 higher expression (EVI1H) in the AML patients; however, the conclusions previously reported have not been fully assessed and are still controversial. Therefore, we performed a meta-analysis to evaluate the prognostic significance of EVI1H in patients with AML. The primary endpoint was overall survival (OS), and the event-free survival (EFS) was selected as the secondary endpoint. We extracted the hazard ratio (HR) and their 95% confidence interval (CI) for the OS and EFS from the multivariate COX proportional hazard models. A total of 4767 AML patients from 11 studies up to 23 February 2019 were subjected to our meta-analysis. Pooled HRs suggested that EVI1H had an adverse impact on OS (HR = 1.52, 95%CI 1.24-1.86) and EFS (HR = 1.41, 95%CI 1.14-1.74) in AML patients. EVI1H was also associated with a shorter OS (HR = 1.73, 95%CI 1.43-2.11) and EFS (HR = 1.17, 95%CI 1.05-1.31) in AML patients with the intermediate cytogenetic risk (ICR) according to the National Comprehensive Cancer Network (NCCN), European leukemia network (ELN), or International System for Human Cytogenetic Nomenclature (ISCN). Furthermore, EVI1H appeared to be a poor prognosis indicator in patients with normal cytogenetics (NC) (HR for OS:2.01, 95%CI 1.32-3.05; HR for EFS 1.54, 95%CI 1.09-2.17) and young patients (HR for OS 1.30, 95%CI 1.09-1.55), respectively. This meta-analysis indicates EVI1H has an independent and significantly adverse prognostic impact on AML patients in the entire population, and this conclusion same applies to some subgroups like AML patients with ICR, NC, and young AML patients.

中文翻译：

---

EVI1基因表达在急性髓性白血病患者中的预后意义：荟萃分析。

嗜统性病毒整合位点1（EVI1）在急性髓细胞性白血病（AML）患者中经常表达。许多研究报告了AML患者中EVI1高表达（EVI1H）对预后的潜在不良影响；但是，先前报道的结论尚未得到充分评估，仍然存在争议。因此，我们进行了荟萃分析以评估EVI1H在AML患者中的预后意义。主要终点是总体生存期（OS），无事件生存期（EFS）被选为次要终点。我们从多元COX比例风险模型中提取了OS和EFS的风险比（HR）及其95％置信区间（CI）。截至2019年2月23日，来自11项研究的4767名AML患者接受了我们的荟萃分析。汇总的HR提示，EVI1H对AML患者的OS（HR = 1.52，95％CI 1.24-1.86）和EFS（HR = 1.41，95％CI 1.14-1.74）有不利影响。根据美国国家综合报道，EVI1H还与中度细胞遗传风险（ICR）的AML患者的OS短（HR = 1.73，95％CI 1.43-2.11）和EFS（HR = 1.17，95％CI 1.05-1.31）相关。癌症网络（NCCN），欧洲白血病网络（ELN）或国际人类细胞遗传命名系统（ISCN）。此外，对于具有正常细胞遗传学（NC）（OS的HR：2.01，95％CI 1.32-3.05； EFS 1.54的HR，95％CI 1.09-2.17）和年轻患者（HR的HR），EVI1H似乎是不良的预后指标。 OS 1.30，95％CI 1.09-1.55）。这项荟萃分析表明，EVI1H对整个人群中的AML患者具有独立且显着不利的预后影响，